One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Scinai Immunotherapeutics Ltd.
SCNI · NCM · Healthcare · Biotechnology
Current price
$0.48
52-week range
$0.39 - $13.00
Market cap
$1.28M
Balance sheet
Distressed
-21.01x Concerning
Net debt $1.68M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Revenue grew 99.2% last year.
- Risk Return on equity was -26.1% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 2.7% (peer median: 9.2%).
What this company does
Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. is a company that develops medicines for immune system diseases and also helps other small biotech companies make their experimental drugs through its contract services. The money it makes comes from selling these drug development services, which matters because it provides a more stable income stream while its own experimental medicines are still in development.
How the company got here
Scinai Immunotherapeutics Ltd. was founded in 2003 under the name BiondVax Pharmaceuticals Ltd. and is based in Jerusalem, Israel. The company has undergone a significant transformation, including a name change to Scinai Immunotherapeutics Ltd. in September 2023 to better reflect its evolving focus. This rebranding signifies a strategic shift in its business direction, moving towards developing innovative treatments for immune-related conditions. The company's journey has been marked by research and development efforts aimed at creating novel therapeutic solutions.
What it actually does
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. Their core work involves researching and creating new medicines, particularly antibody-based therapies. These therapies are designed to target specific parts of the immune system to help manage conditions where the body's own defenses are causing harm. The company also provides services to other biotech firms, helping them develop and manufacture their own drug candidates.
IL-17 NanoAb Platform
This business line centers on Scinai's proprietary IL-17 NanoAb platform, which uses a special type of antibody (VHH-based) to treat immune-related and inflammatory diseases. A key focus area for this platform is psoriasis, a chronic skin condition causing red, itchy patches. The goal is to develop targeted therapies that can offer relief to patients suffering from such conditions. This represents a significant part of the company's research and development efforts.
PC111 Monoclonal Antibody
Scinai is developing PC111, a human monoclonal antibody designed to treat severe skin conditions like pemphigus, Steven Johnson's syndrome, and toxic epidermal necrolysis. These are serious autoimmune disorders where the immune system attacks the skin. PC111 is a type of biologic drug, meaning it's made from living cells, and it's engineered to precisely target the cause of these diseases. This program represents another key therapeutic area for the company.
Contract Development and Manufacturing Organization (CDMO) Services
Beyond its own drug development, Scinai offers services to other early-stage biotechnology companies. These services include analytical method development (figuring out how to test drug quality), process development (designing how to make the drug), and cGMP manufacturing (producing clinical-stage materials in a way that meets strict quality standards). This segment acts as a revenue stream and leverages the company's expertise and facilities to support the broader biotech industry.
What management is betting on now
Management is focused on advancing their pipeline of innovative antibody-based therapies, particularly the IL-17 NanoAb platform for inflammatory diseases and PC111 for severe skin conditions. They are also leveraging their contract development and manufacturing capabilities to generate revenue and support other biotech companies. Strategic collaborations with institutions like Max Planck Society and University Medical Center Gottingen are crucial for developing new NanoAb candidates. These efforts aim to bring novel treatments to market and solidify Scinai's position in the biopharmaceutical landscape.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-6.35M
FY2025 Q4
$-6.05M
Revenue
$1.31M
Net income
$-8.31M
Diluted EPS
—
Operating cash flow
$-6.03M
Free cash flow
$-6.05M
Fetching…
Sources
Revenue
$658.00K
Net income
$4.80M
Diluted EPS
—
Operating cash flow
$-6.33M
Free cash flow
$-6.35M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.48
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net debt $1.7M. Interest coverage -21.0x.
Net debt
$1.68M
Interest coverage
-21.01x
Scinai Immunotherapeutics Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 4 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
SCNI
BASELINE
Scinai Immunotherapeutics Ltd.
Total debt $3.39M Interest coverage -21.01x This is the baseline the peer rows are being compared against.
Total debt $5.46M Interest coverage -36.22x Neither company has much profit cushion over interest right now.
Total debt $101.62K Interest coverage -37.39x Neither company has much profit cushion over interest right now.
Total debt $369.70K Interest coverage -438.08x Neither company has much profit cushion over interest right now.
Total debt $273.92K Interest coverage -55.36x Neither company has much profit cushion over interest right now.
What you should know
The case for and against SCNI
1 Reward
2 Risks
Rewards
-
Revenue grew 99.2% last year.
Risks
-
Return on equity was -26.1% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 2.7% (peer median: 9.2%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
0.02x
Forward P/E
—
P/B
0.13x
P/S
0.42x
EV/EBITDA
-1.22x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-121.1%
Operating margin
-105.1%
Net margin
-80.1%
ROE
-26.1%
ROA
-38.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.32x
Current ratio
1.23x
Quick ratio
0.97x
Total debt
$3.39M
Total cash
$1.71M
Growth
How the business has been compounding
Revenue TTM
$1.31M
Revenue 5Y CAGR
99.2%
EPS TTM
28.07
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-21.75M
Free CF TTM
$-6.05M
FCF margin
-461.9%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—